|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500108092 |
|
最近更新日期: Date of Last Refreshed on: |
2025-08-25 11:07:41 |
|
注册时间: Date of Registration: |
2025-08-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
前瞻性评价复方甘菊利多卡因凝胶对经鼻气管插管患者并发症的影响:一项随机平行对照研究 |
|
Public title: |
Prospective evaluation of the effect of compound chamomile lidocaine gel on complications in patients undergoing nasal tracheal intubation: A randomized parallel controlled study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
前瞻性评价复方甘菊利多卡因凝胶对经鼻气管插管患者并发症的影响:一项随机平行对照研究 |
|
Scientific title: |
Prospective evaluation of the effect of compound chamomile lidocaine gel on complications in patients undergoing nasal tracheal intubation: A randomized parallel controlled study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
罗薇 |
研究负责人: |
吉阳 |
|
Applicant: |
Luo Wei |
Study leader: |
Ji Yang |
|
申请注册联系人电话: Applicant telephone: |
+86 185 8307 6242 |
研究负责人电话: Study leader's telephone: |
+86 136 6626 4254 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
luo_wei1027@163.com |
研究负责人电子邮件: Study leader's E-mail: |
yangji7799@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市人民南路三段14号 |
研究负责人通讯地址: |
四川省成都市人民南路三段14号 |
|
Applicant address: |
No. 14, Section 3, Renmin South Road, Chengdu City, Sichuan Province |
Study leader's address: |
No. 14, Section 3, Renmin South Road, Chengdu City, Sichuan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西口腔医院 |
||
|
Applicant's institution: |
West China School/Hospital of Stomatology Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西口腔医院 |
||
|
Affiliation of the Leader: |
West China School/Hospital of Stomatology Sichuan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
WCHSIRB-D-2025-342-R1 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西口腔医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of West China Hospital of Stomatology, Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-08-15 00:00:00 |
||
|
伦理委员会联系人: |
李灏来 |
||
|
Contact Name of the ethic committee: |
Li Haolai |
||
|
伦理委员会联系地址: |
四川省成都市人民南路三段14号 |
||
|
Contact Address of the ethic committee: |
No. 14, Section 3, Renmin South Road, Chengdu City, Sichuan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8550 3503 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西口腔医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China School/Hospital of Stomatology Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市人民南路三段14号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 14, Section 3, Renmin South Road, Chengdu City, Sichuan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
经费自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-financed funds |
||||||||||||||||||||||
|
Target disease: |
Postoperative nasopharyngeal complications after nasal intubation |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.评价复方甘菊利多卡因凝胶对全麻手术经鼻气管插管患者有效性和安全性; 2.评价复方甘菊利多卡因凝胶在全麻手术经鼻气管插管过程中,对于减少并发症和患者获益的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.To evaluate the efficacy and safety of compound chamomile lidocaine gel in patients undergoing nasal tracheal intubation under general anesthesia. 2.To assess the impact of compound chamomile lidocaine gel on reducing complications and patient benefits during nasal tracheal intubation under general anesthesia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.拟行经鼻气管插管全身麻醉下择期手术的患者; 2.全身麻醉进行双侧颞下颌关节盘锚固术患者,手术时长2-4h,年龄18-65岁; 3.美国麻醉医师协会(ASA)分级Ⅰ~Ⅱ级; 4.体重指数(body mass index, BMI)18~27 kg/m2; 5.签署研究知情同意书; |
||||||||||||||||||||||
|
Inclusion criteria |
1.Patients scheduled for elective surgery under general anesthesia with nasal tracheal intubation; 2.Patients undergoing bilateral temporomandibular joint disc anchoring surgery under general anesthesia, with a surgery duration of 2-4 hours, aged 18-65 years; 3.American Society of Anesthesiologists (ASA) physical status classification I-II; 4.Body mass index (BMI) 18-27 kg/m^2; 5.Signed informed consent form for the study. |
||||||||||||||||||||||
|
排除标准: |
1.鼻腔肿物、如颅面部骨折、严重鼻中隔偏曲或鼻甲肥大导致无法通过导管、先天性后鼻孔闭锁、急性颅脑损伤伴颅内压升高、急性鼻窦炎或鼻腔感染未控制、脑膜炎或颅内感染、骨髓移植患者(鼻腔菌群易引发全身感染)、系统性红斑狼疮; 2.呼吸道梗阻或咽部脓肿; 3.鼻部骨折、颅底骨折伴脑脊液漏患者; 4.既往鼻腔手术史或外伤史; 5.药物成份过敏者; 6.预期的困难气道; 7.其他不适合临床试验者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Nasal tumors, such as craniofacial fractures, severe nasal septum deviation or hypertrophy of the nasal conchae, which prevent the passage of the catheter; congenital posterior nasal passage closure; acute craniocerebral injury with increased intracranial pressure; acute sinusitis or nasal infection not controlled; meningitis or intracranial infection; bone marrow transplant patients (nasal flora is prone to cause systemic infections); systemic lupus erythematosus; 2.Respiratory tract obstruction or pharyngeal abscess; 3.Nasal fractures, patients with cranial base fractures and cerebrospinal fluid leakage; 4.Previous history of nasal surgery or trauma; 5.Individuals with drug component allergies; 6.Expected difficult airway; 7.Other individuals not suitable for clinical trials. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-08-21 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-09-01 00:00:00 至 To 2026-08-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用简单随机分组的方法,患者签署书面知情同意书后,一名研究者将使用有顺序编号的密封不透明信封将连续的参与者随机分配到两组,该信封内装有随机分组信息。一位没有进一步参与试验的独立管理员事先准备了这些信封。信封上标明了患者的详细信息,以记录随机化是按照招募顺序进行的。随机序列是由基于https://www.randomizer.org/网站上创建的随机列表(1:1)产生. |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
In this study, a simple random grouping method was adopted. After the patients signed the written informed consent form, a researcher would use sequentially numbered sealed opaque envelopes to randomly assign consecutive participants to the two groups. The envelopes contained the information for random grouping. An independent administrator who did not further participate in the trial had prepared these envelopes in advance. The envelopes were marked with the detailed information of the patients to record that the randomization was carried out according to the recruitment order.The random sequence is generated from a random list (1:1) created based on the website https://www.randomizer.org/ |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Date Capture System |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |